Ascendis Pharma's TransCon CNP Shows Sustained Improvements in Achondroplasia Trial
Event summary
- Ascendis Pharma's TransCon CNP demonstrated continued improvements in lower extremity alignment through Week 104 of the ApproaCH Trial.
- Children with preexisting genu varum (leg bowing) showed greater improvements in tibial-femoral angle (TFA).
- TransCon CNP was generally well tolerated, with no symptomatic hypotension or acceleration of bone age reported.
- The U.S. FDA approved TransCon CNP under the trade name YUVIWEL® in February 2026; European approval anticipated in Q4 2026.
The big picture
Ascendis Pharma's TransCon CNP represents a significant advancement in the treatment of achondroplasia, addressing serious complications such as chronic pain and altered mobility. The sustained improvements in lower extremity alignment and growth velocity highlight the potential of this therapy to become a cornerstone treatment for this rare genetic condition. With FDA approval already secured and European approval on the horizon, Ascendis is poised to expand its reach in the rare disease market.
What we're watching
- Regulatory Approval
- Whether the European Medicines Agency will approve YUVIWEL in Q4 2026, expanding market access for TransCon CNP.
- Clinical Efficacy
- The long-term sustainability of improvements in lower extremity alignment and growth velocity with continued TransCon CNP treatment.
- Market Penetration
- How Ascendis Pharma will position YUVIWEL against existing treatments for achondroplasia and capture market share.